EAHAD 2020 is taking place from 4-7 February under the direction of Congress President, Prof. Dr. Karin Fijn van Draat. The theme of this year’s Congress is “A Golden Age of Treatment Choice”.
Prof. Dr. Karin Fijn van Draat is not only a member of the EAHAD Executive Committee, but also the President of our 2020 Congress taking place from 5 to 7 February 2020 in The Hague, Netherlands. In the lead up to our 13th annual meeting, we had the opportunity to speak with Prof. Fijn van Draat about her background, the most rewarding and challenging aspects of being this year’s Congress President, as well as her views on what the future key issues will be in the haemophilia and allied disorders field in Europe.
Continuing their pursuit of building a community of psychologists and social workers involved in the bleeding disorders field in Europe, the EAHAD Psychosocial Professionals Working Group will dedicate the third and final part of their EAHAD 2020 Pre-Congress Day Programme to a brainstorming session on building a network of European peers and colleagues.
The EAHAD 2020 Annual Congress will take place in The Hague, Netherlands, from 5 to 7 February 2020 at the World Forum congress centre.
Congress President Prof. Karin Fijn van Draat, with the support of the Congress Organising Committee, has put together an insightful programme, full of interesting sessions on the most pressing issues in haemophilia and bleeding disorders care today. With the theme “A Golden Age for Treatment Choice”, the programme pays homage to Dutch history and the legacy of 17th century art on display in The Hague, while highlighting the exciting period we find ourselves in in terms of haemophilia treatment and the many considerations that clinicians and patients must take into account.
By Christopher Ludlam, Chairman, and Geoffrey Kemball-Cook, Secretary, EAHAD-DB Coagulation Factor Variant Database Steering Group
The EAHAD Coagulation Factor Databases have recently been enhanced with new features and a greatly increased number of listed variants. The databases are now hosted at a new address http://dbs.eahad.org and you are encouraged to visit the site and review the variant lists, clinical information, and a host of additional information about the individual clotting factors, including comprehensive references and graphic display on molecular models of the site of variants.
We were saddened to hear of the passing of Professor Jørgen Ingerslev earlier this month.
Prof. Ingerslev was a world leading specialist in the haemophilia and bleeding disorders field. Recognised for his knowledge and dedication to his profession, he had an extensive output of research publications and was a frequent speaker at conferences and symposia around the world.
The European Haemophilia Consortium’s (EHC) inaugural Conference on Women and Bleeding Disorders took place in Frankfurt, Germany, from Friday 24 to Sunday 26 May. It brought together close to 150 delegates, including patient representatives from around 30 countries.
The 2020 EAHAD Research Grant call for applications is now open. The application cycle runs from July to October of each year and the winner is announced at the annual EAHAD Congress in February.
EUHASS is a pharmacovigilance programme monitoring the safety of treatments for people with inherited bleeding disorders in Europe. Haemophilia treatment centres report adverse events directly to the EUHASS website where a live tally of reported events can be viewed. Quarterly and yearly surveillance reports are produced and made available to participating centres and product manufacturers, whilst product-specific reports are only shared with regulators and product manufacturers.
Following a unanimous decision on Thursday 7 February 2019 at the Annual General Meeting, EAHAD officially transferred its legal base from the United Kingdom to Belgium. Therefore, EAHAD is now an international non-profit association (AISBL) under Belgian law.